Search

Search Constraints

You searched for: Author/Creator Gilabert, P

Search Results

1. Inflammatory Bowel Disease (IBD) and immunosuppression do not worsen the prognosis of COVID-19. Results from the ENEIDA Project of GETECCU. (27th May 2021)

2. P162 RAID-Monitor: a new non-invasive method to determine endoscopic activity in inflammatory bowel diseases. (25th January 2019)

3. P213 RAID-IBS Diagnosis: A new non-invasive method to support Irritable Bowel Syndrome diagnosis. (16th January 2018)

4. P251 RAID Dx: the first test based on faecal microbiota to differentiate irritable bowel syndrome from inflammatory bowel diseases. (25th January 2019)

5. P318 Association between faecal calprotectin values and infliximab trough levels in inflammatory bowel disease patients. (16th January 2018)

6. P386 Clinical presentation, management, and evolution of lymphomas in patients with Inflammatory Bowel Disease: an ENEIDA registry study. (30th January 2023)

7. P635 Carriage of the HLA-DQA1*05 allele is associated with a high risk of loss of response to infliximab in patients with inflammatory bowel disease. (25th January 2019)

8. P645 Pharmacokinetics and immunogenicity of Infliximab biosimilar in inflammatory bowel disease patients. (25th January 2019)

9. P674 Definition of a microbial signature as a predictor of anti-TNFα treatment response. (27th May 2021)

10. P761 IFX dose-escalation strategy based on a population PK model in IBD patients with secondary loss of response. (16th January 2018)